by Tony Jones, CEO, One Nucleus Collaboration is Key Whilst the four events detailed below remain fully independent, they offer a valuable co-location in one city of over 1000 collective event attendees active in basic or translational research and the business of collaboration and investment in bio-innovation. Each event has a clarity of purpose for its audience, but by opening the Genesis conference app to both Genesis attendees and non-attendees, the opportunity is provided for all to connect and meet across the week, even if attending different events. A great opportunity for:…

It may feel peculiar to state, but entering award competitions is not only about walking away with the trophy on the night when it comes to what’s good for your business. Of course, nothing quite replaces the feeling of being recognised as a winner by your peers, but when it comes to a high-quality and competitive landscape such as the Life Sciences sector, the benefits of getting involved at all can be impressive. The positives commence from the moment of nomination and the actions you then take between entry submission and the gala awards dinner. It is as true for award competitions as it…

The September edition of our People Pathways newsletter is now available to read here! Featuring:✅ One Nucleus upcoming courses✅ Training Course Spotlight: Presentation Skills for Life Science Professionals✅ One Nucleus Support Initiative for Life Science Employees Between Jobs - a reminder of the support available✅ A recent Nature feature spotlighting a radically different model of higher education

LONDON, UK and BASEL, Switzerland - September 25, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, announces the appointment of Sabine Moravi as an Associate Partner. This strategic hire marks a significant step in the firm’s expansion within the Swiss market and the broader DACH region.Sabine Moravi brings over 20 years of leadership experience across the global life sciences industry, with a rare combination of executive, investor-facing, and operational expertise. She advises companies ranging from global…

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc (“Arecor” or the “Company”) Co-development Agreement with US Insulin Pump Device Company for AT278 and Sale of Royalty and Technology Access Fees for up to $11 million - AT278 (500U/mL) is the only ultra-concentrated and ultra-rapid acting insulin in development designed to enable the next generation of longer-wear and miniaturised automated insulin delivery (AID) systems - Arecor and Sequel Med Tech, LLC to…

Fierce 15 highlights pre-commercial biotech companies driving the next generation of therapies for patients worldwide   Cambridge, UK, 22 September 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates to combat neurodegenerative diseases, today announced that it has been named as one of Fierce Biotech’s 2025’s ‘Fierce 15’ for 2025. The selection recognises the Company as one of the most innovative and promising private biotechnology companies in the industry. TRIMTECH is addressing the urgent need for cost-…

Oxford, UK – 22nd September 2025. OGT, a leading global provider of genomic diagnostic and research solutions, announced today that the U.S. Food and Drug Administration (FDA) has granted their De Novo Classification Request for the CytoCell® KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic (CDx) for Syndax’s first-in-class menin inhibitor, REVUFORJ® (revumenib). Revuforj is FDA approved for the treatment of relapsed or refractory (R/R) acute leukaemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and paediatric patients one year and older. OGT’s…

• Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success; former CEO Robin Carr transitions to new CTO role • Expanded senior team across clinical, CMC, regulatory and business development in the US and UK • Global leader in developing a novel and highly differentiated payload class for ADCs, NMTi (N-myristoyltransferase inhibitors), to address the critical need to overcome payload resistance and improve tolerability • On track to enter the clinic with lead NMTi-ADC candidate, following…

There are many different types of cells in the brain. We know that in Parkinson’s, brain cells that produce dopamine become damaged and start to die over time. However, it’s possible that other types of brain cells could also become damaged, and they may even play a role in why dopamine cells become unwell. Dr Nataly Hastings at Cellestial Health is leading a team of researchers to explore how a previously overlooked type of brain cell, called an astrocyte, could be involved in Parkinson’s. Astrocytes are star-shaped brain cells that form large networks in the brain. Within these networks,…

KRAS is one of the most frequently mutated oncogenes in human cancers. Once thought “undruggable,” recent scientific advances have enabled the development of therapies targeting KRAS mutations, especially G12C, G12D, and G13D. At Medicilon, we provide integrated preclinical services to support KRAS-targeted drug discovery and development: ✅ Drug discovery ✅ CMC research (API + formulation) ✅ Pharmacodynamics study ✅ Pharmacokinetics (PK) analysis ✅ Safety evaluation Understanding KRAS: https://pubmed.ncbi.nlm.nih.gov/31649840/ KRAS functions as a molecular switch, cycling between GDP-…